Skip to main content
PharmaCielo Ltd. logo

PharmaCielo Ltd. — Investor Relations & Filings

Ticker · PCLO ISIN · CA71716K1012 LEI · 5493002XOFWMT83TYQ57 TSXV Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2020-08-18 Call Transcript
Country CA Canada
Listing TSXV PCLO

About PharmaCielo Ltd.

https://www.pharmacielo.com/

PharmaCielo Ltd. is a global supplier specializing in the cultivation, processing, and distribution of medicinal-grade cannabis extracts and dried flower. The company focuses on ethical and sustainable production, aiming to be a leading partner in the global medicinal cannabis market. Utilizing ideal equatorial conditions, PharmaCielo operates large-scale, high-efficiency production facilities, including 12 hectares of open-air greenhouses, enabling four full crops annually for reliable supply. Its product portfolio includes standardized extracts, such as high-purity CBD Isolate, and both psychoactive and non-psychoactive derivatives. Production adheres to pharmaceutical-quality standards, supported by proprietary genetics maintained in a tissue culture lab and advanced processing facilities ensuring consistency and safety.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Call Transcript Classification · 90% confidence The document is a press release announcing a conference call to discuss the company's second quarter 2020 financial results. It provides details about the call date, time, and participants but does not contain any actual financial data or the financial report itself. The document length is short (2753 characters), and it explicitly states the event to review financial results rather than presenting the results. Therefore, this is a Call Transcript announcement or invitation, not the transcript itself. According to the filing definitions, this fits best under Call Transcript (CT) as it relates to a conference call about financial results.
2020-08-18 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing PharmaCielo's activation of an external cultivation contract to expand cannabis cultivation capacity. It discusses operational expansion, contract details, and forward-looking statements about production and licensing. There are no financial statements, regulatory filings, or detailed financial data presented. The content is primarily a corporate update on business operations and strategy rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is also not a Management or Board announcement, nor a legal or governance document. The document is best classified as a Regulatory Filing (RNS) because it is a general corporate announcement that does not fit other specific categories.
2020-08-13 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'PharmaCielo Announces Results of AGM' and details the voting results from the Annual General Meeting held on August 6, 2020. It includes vote percentages for director elections and auditor appointment, as well as shareholder attendance information. There is no detailed financial data or comprehensive report content, only the announcement of voting outcomes. The document also references the Management Proxy Circular for more information and provides a link to the AGM audio recording. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)' rather than the full AGM materials or annual report. The document length is about 4820 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2020-08-07 English
Notice of meeting - English.pdf
Regulatory Filings
2020-07-15 English
News release - English.pdf
Regulatory Filings
2020-07-08 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Form 51-102F3 MATERIAL CHANGE REPORT' and details a material change event regarding the completion of a $4.6 million bought deal offering by PharmaCielo Ltd. It includes specifics about the offering, such as the number of shares issued, price, underwriters, and use of proceeds. The document is a regulatory filing reporting a material change event, which is a common type of disclosure under Canadian securities regulations. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. The content focuses on a financing event, specifically a bought deal offering, which aligns with updates on company fundraising or capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3531 characters, which is sufficient to contain substantive information about the financing event rather than just a brief announcement. Hence, the confidence in this classification is high.
2020-07-06 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.